Do you want to read an article? Please log in or register.
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Cardiovascular Risk and Diseases
COMMENTED
Related content
Cardiovascular Risk and Diseases
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial
Lancet Diabetes Endocrinol
Hauge JW, Borgeraas H, Birkeland KI, Johnson LK, Hertel JK, Hagen M, Gulseth HL, Lindberg M, Lorentzen J, Seip B, Kolotkin RL, Svanevik M, Valderhaug TG, Sandbu R, Hjelmesæth J, Hofsø D
doi: 10.1016/S2213-8587(24)00396-6
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8
Cardiovascular Risk and Diseases
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics
Cardiovasc Diabetol
Xie R, Seum T, Sha S, Trares K, Holleczek B, Brenner H, Schöttker B
doi: 10.1186/s12933-025-02581-3
Further Publications
Genetic Susceptibility to Type 2 Diabetes, Television Viewing, and Atherosclerotic Cardiovascular Disease Risk
J Am Heart Assoc
Wang M, Collings PJ, Day FR, Ong KK, Brage S, Sharp SJ, Jang H, Suh S, Luo S, Au Yeung SL, Kim Y
doi: 10.1161/JAHA.124.036811
Heart, Artery and Coronary Diseases
Encouraging the prescribing of SGLT2i and GLP-1RA medications to reduce cardiovascular and renal risk in patients with type 2 diabetes: rationale and design of a randomized controlled trial
Am Heart J
Haff N, Horn DM, Bhatkhande G, Sung M, Colling C, Wood W, Robertson T, Gaposchkin D, Simmons L, Yang J, Yeh J, Crum KL, Hanken KE, Lauffenburger JC, Choudhry NK
doi: 10.1016/j.ahj.2025.02.007
Heart Failure
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
N Engl J Med
Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Treppendahl MB, Verma S, Jensen TJ, Liisberg K, Lindegaard ML, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Shah SJ, STEP-HFpEF DM Trial Committees and Investigators
doi: 10.1056/NEJMoa2313917
Cardiovascular Risk and Diseases
Bempedoic Acid Reduces the Risk of Major Adverse Cardiovascular Events Across Patient Subgroups
Cardiovascular Risk and Diseases
Risk acceleration by gout on major adverse cardiovascular events and all-cause death in patients with diabetes and chronic kidney disease
Diabetes Obes Metab
Lee DY, Moon JS, Jung I, Chung SM, Park SY, Yu JH, Seo JA, Han KD, Kim NH
doi: 10.1111/dom.16165
COMMENTED
Cardiovascular Risk and Diseases
The Frequency of Undiagnosed Celiac Disease in Youth with Type 1 Diabetes and Its Association with Diabetic Retinopathy: The SEARCH for Diabetes in Youth Study
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Pediatr Diabetes
Brady RP, Jensen ET, Rigdon J, Crimmins NA, Mallon D, Dolan LM, Imperatore G, Kahkoska AR, Mottl AK, Honor A, Pettitt DJ, Merjaneh L, Dabelea D, Shah AS
doi: 10.1155/2023/9038795